Survival in Imatinib-Treated CML Independent of Response Time Survival in Imatinib-Treated CML Independent of Response Time

The 10-year survival analysis shows no significant difference in outcomes based on imatinib regimen, including higher dose that has previously been linked to a faster response.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news